• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾病性胱氨酸病:半胱胺治疗眼部病变无效。

Nephropathic cystinosis: ineffectiveness of cysteamine therapy for ocular changes.

作者信息

Cantani A, Giardini O, Ciarnella Cantani A

出版信息

Am J Ophthalmol. 1983 May;95(5):713-4. doi: 10.1016/0002-9394(83)90401-4.

DOI:10.1016/0002-9394(83)90401-4
PMID:6846466
Abstract

The biochemical hallmark of nephropathic cystinosis is the intralysosomal accumulation of free cystine in various organs, including the conjunctiva, cornea, bone marrow, leukocytes, lymph nodes, and internal organs. A patient with the infantile form of nephropathic cystinosis develops several renal tubular malfunctions during the first year of life; these eventually lead to end-stage renal failure and eventual death by the time the patient is 10 years of age. Ocular changes are prominent and may be so typical that an early diagnosis can be achieved by an ophthalmologic examination before the nephropathic signs become evident.

摘要

肾病型胱氨酸病的生化特征是游离胱氨酸在包括结膜、角膜、骨髓、白细胞、淋巴结和内脏等多种器官的溶酶体内蓄积。患有婴儿型肾病型胱氨酸病的患者在出生后第一年就会出现多种肾小管功能障碍;这些最终会导致终末期肾衰竭,并在患者10岁时最终死亡。眼部变化很突出,可能非常典型,以至于在肾病症状明显之前通过眼科检查就能早期诊断。

相似文献

1
Nephropathic cystinosis: ineffectiveness of cysteamine therapy for ocular changes.肾病性胱氨酸病:半胱胺治疗眼部病变无效。
Am J Ophthalmol. 1983 May;95(5):713-4. doi: 10.1016/0002-9394(83)90401-4.
2
Long-term treatment of infantile nephropathic cystinosis with cysteamine.用半胱胺对婴儿肾病性胱氨酸病进行长期治疗。
N Engl J Med. 1985 Dec 5;313(23):1460-3. doi: 10.1056/NEJM198512053132307.
3
Adverse reactions to oral cysteamine use in nephropathic cystinosis.肾病性胱氨酸病口服半胱胺的不良反应。
Dev Pharmacol Ther. 1981;3(1):25-30. doi: 10.1159/000457418.
4
Nephropathic cystinosis: posterior segment manifestations and effects of cysteamine therapy.肾性胱氨酸病:眼部后段表现及半胱胺治疗的效果
Ophthalmology. 2006 Jun;113(6):1002-9. doi: 10.1016/j.ophtha.2005.12.026. Epub 2006 Apr 17.
5
Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.肾病性胱氨酸病患者从速释型半胱胺转换为缓释型半胱胺:一项回顾性真实单中心研究。
Pediatr Nephrol. 2017 Jan;32(1):91-97. doi: 10.1007/s00467-016-3438-x. Epub 2016 Jun 27.
6
Cysteamine therapy for children with nephropathic cystinosis.半胱胺治疗肾病型胱氨酸病患儿。
N Engl J Med. 1987 Apr 16;316(16):971-7. doi: 10.1056/NEJM198704163161602.
7
Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops.肾病性胱氨酸病中的角膜晶体:自然病史及半胱胺滴眼液治疗
Mol Genet Metab. 2000 Sep-Oct;71(1-2):100-20. doi: 10.1006/mgme.2000.3062.
8
Beneficial effects of starting oral cysteamine treatment in the first 2 months of life on glomerular and tubular kidney function in infantile nephropathic cystinosis.胱胺治疗在生命的头 2 个月开始对婴儿胱氨酸病的肾小球和肾小管肾脏功能的有益影响。
Mol Genet Metab. 2022 Aug;136(4):282-288. doi: 10.1016/j.ymgme.2022.06.009. Epub 2022 Jul 1.
9
Parenchymal organ cystine depletion with long-term cysteamine therapy.长期使用半胱胺治疗导致实质器官胱氨酸耗竭。
Biochem Med Metab Biol. 1992 Dec;48(3):275-85. doi: 10.1016/0885-4505(92)90074-9.
10
Ocular manifestations of nephropathic cystinosis. The French-Canadian experience in a genetically homogeneous population.肾病性胱氨酸病的眼部表现。法裔加拿大人在基因同质人群中的经验。
Arch Ophthalmol. 1991 Mar;109(3):359-62. doi: 10.1001/archopht.1991.01080030061039.

引用本文的文献

1
Long-term follow-up of cystinosis patients treated with 0.55% cysteamine hydrochloride.胱氨酸病患者接受 0.55%盐酸半胱氨酸治疗的长期随访。
Br J Ophthalmol. 2021 May;105(5):608-613. doi: 10.1136/bjophthalmol-2020-316450. Epub 2020 Jun 27.
2
Effect of Storage Conditions on Stability of Ophthalmological Compounded Cysteamine Eye Drops.储存条件对复方半胱胺滴眼液稳定性的影响
JIMD Rep. 2018;42:47-51. doi: 10.1007/8904_2017_77. Epub 2017 Dec 7.
3
Treatment of Inherited Eye Defects by Systemic Hematopoietic Stem Cell Transplantation.
通过全身造血干细胞移植治疗遗传性眼部缺陷
Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7214-23. doi: 10.1167/iovs.15-17107.
4
Improving the prognosis of nephropathic cystinosis.改善肾病型胱氨酸病的预后。
Int J Nephrol Renovasc Dis. 2014 Jul 17;7:297-302. doi: 10.2147/IJNRD.S37603. eCollection 2014.
5
Evaluation of topical cysteamine therapy in the CTNS(-/-) knockout mouse using in vivo confocal microscopy.使用体内共聚焦显微镜评估CTNS(-/-)基因敲除小鼠的局部半胱胺治疗效果。
Mol Vis. 2011;17:2649-54. Epub 2011 Oct 8.
6
Quantitative in vivo and ex vivo confocal microscopy analysis of corneal cystine crystals in the Ctns knockout mouse.Ctns基因敲除小鼠角膜胱氨酸晶体的体内和体外定量共聚焦显微镜分析
Mol Vis. 2011;17:2212-20. Epub 2011 Aug 17.
7
Ophthalmic manifestations and histopathology of infantile nephropathic cystinosis: report of a case and review of the literature.婴儿型肾病性胱氨酸病的眼部表现及组织病理学:一例报告并文献复习
Surv Ophthalmol. 2007 Jan-Feb;52(1):97-105. doi: 10.1016/j.survophthal.2006.10.006.
8
A multicentre randomised double masked clinical trial of a new formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis.一项关于新型局部用半胱胺制剂治疗胱氨酸病角膜胱氨酸结晶的多中心随机双盲临床试验。
Br J Ophthalmol. 2003 Jan;87(1):28-31. doi: 10.1136/bjo.87.1.28.
9
Cysteamin eyedrops in three patients with nephropathic cystinosis.胱胺滴眼液治疗三名肾病性胱氨酸病患者。
Doc Ophthalmol. 1996;92(1):51-3. doi: 10.1007/BF02583276.
10
Update on nephropathic cystinosis.肾性胱氨酸病的最新进展。
Pediatr Nephrol. 1990 Nov;4(6):645-53. doi: 10.1007/BF00858644.